Vir Biotechnology, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Vir Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.44M, a 121.88% increase year-over-year.
- Vir Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $174.00K, a 70.90% decline year-over-year.
- Vir Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $1.00K, a 98.88% decline year-over-year.
- Vir Biotechnology, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $101.00K, a 42.25% increase year-over-year.
- Vir Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $1.35M, a 70.76% increase from fiscal 2024.
- Vir Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $790.00K, a 77.32% decline from fiscal 2023.
- Vir Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $3.48M, a 23.16% decline from fiscal 2022.
- Vir Biotechnology, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $4.53M, a 65.33% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.44M 10-Q · filed 2026-08-05 | $1.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $174.00K 10-Q · filed 2026-05-07 | $925.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.35M 10-K · filed 2026-02-23 |
| 2025-09-30 | $101.00K 10-Q · filed 2025-11-05 | $1.44M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $649.00K 10-Q · filed 2026-08-05 | $1.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $598.00K 10-Q · filed 2026-05-07 | $1.17M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $790.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $71.00K 10-Q · filed 2025-11-05 | $790.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $410.00K 10-Q · filed 2025-08-06 | $1.06M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $220.00K 10-Q · filed 2025-05-08 | $1.39M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $3.48M 10-K · filed 2026-02-23 |
| 2023-09-30 | $343.00K 10-Q · filed 2024-11-04 | $4.33M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $742.00K 10-Q · filed 2024-08-01 | $6.03M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.31M 10-Q · filed 2024-05-03 | $6.36M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $932.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.53M 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.04M 10-Q · filed 2023-11-03 | $7.04M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $1.07M 10-Q · filed 2023-08-04 | $8.69M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $484.00K 10-Q · filed 2023-05-08 | $11.21M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $13.08M 10-K · filed 2024-02-26 |
| 2021-09-30 | $3.69M 10-Q · filed 2022-11-03 | $10.15M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $3.59M 10-Q · filed 2022-08-09 | $7.62M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $2.35M 10-Q · filed 2022-05-05 | $6.27M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $519.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $4.06M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.15M 10-Q · filed 2021-11-04 | $3.60M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.25M 10-Q · filed 2021-08-05 | $2.81M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $143.00K 10-Q · filed 2021-05-06 | $1.21M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.13M 10-K · filed 2022-02-28 |
| 2019-09-30 | $364.00K 10-Q · filed 2020-11-10 | $1.32M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $635.00K 10-Q · filed 2020-08-11 | $1.27M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $67.00K 10-Q · filed 2020-05-12 | |
| 2018-12-31 | $259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $584.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | $311.00K 10-Q · filed 2019-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |